ReviewInternational journal of molecular sciences2023
A Review of the Molecular Landscape of Adenoid Cystic Carcinoma of the Lacrimal Gland.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Clinical characteristics, management, and outcomes of lacrimal gland adenoid cystic carcinoma: a single-center series with contextual comparison to SEER data.Frontiers in oncology · 2026Article
- A case report of misdiagnosed adenoid cystic carcinoma of the parotid gland on ultrasound: imaging-pathological correlation and diagnostic implications.Gland surgery · 2025Article
- "Hard palate adenoid cystic carcinoma: surgical resection, radiotherapeutic strategy, and long-term surveillance".Radiology case reports · 2025Article
- Development and evaluation of a quality-of-life questionnaire for patients with orbital malignant tumours.BMJ open ophthalmology · 2025Article
- Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review).Oncology letters · 2025Review
- Advances in treatment of adenoid cystic carcinoma of the lacrimal gland.International journal of ophthalmology · 2025Review
- Adenoid cystic carcinoma of the external auditory canal with metastasis to the cerebellopontine angle mimicking vestibular schwannoma: a case report and literature review.Frontiers in oncology · 2025Article
- Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?Cancers · 2024Review
- Prognostic factors for lacrimal gland adenoid cystic carcinoma: a retrospective study in Chinese patients.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoid cystic carcinoma (ACC) has a worldwide incidence of three to four cases per million population. Although more cases occur in the minor and major salivary glands, it is the most common lacrimal gland malignancy. ACC has a low-grade, indolent histological appearance, but is relentlessly progressive over time and has a strong proclivity to recur and/or metastasise. Current treatment options are limited to complete surgical excision and adjuvant radiotherapy. Intra-arterial systemic therapy is a recent innovation. Recurrent/metastatic disease is common due to perineural invasion, and it is largely untreatable as it is refractory to conventional chemotherapeutic agents. Given the rarity of this tumour, the molecular mechanisms that govern disease pathogenesis are poorly understood. There is an unmet, critical need to develop effective, personalised targeted therapies for the treatment of ACC in order to reduce morbidity and mortality associated with the disease. This review details the evidence relating to the molecular underpinnings of ACC of the lacrimal gland, including the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.